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Enrique Alcalde-Cabero1, Javier Almazán-Isla1, Antonio García-Merino2, Joao de Sá3 and Jesús de Pedro-Cuesta1*Abstract
Background: A debate surrounding multiple sclerosis epidemiology has centred on time-related incidence
increases and the need of monitoring. The purpose of this study is to reassess multiple sclerosis incidence in the
European Economic Area.
Methods: We conducted a systematic review of literature from 1965 onwards and integrated elements of original
research, including requested or completed data by surveys authors and specific analyses.
Results: The review of 5323 documents yielded ten studies for age- and sex-specific analyses, and 21 studies for
time-trend analysis of single data sets. After 1985, the incidence of multiple sclerosis ranged from 1.12 to 6.96 per
100,000 population, was higher in females, tripled with latitude, and doubled with study midpoint year. The north
registered increasing trends from the 1960s and 1970s, with a historic drop in the Faroe Islands, and fairly stable
data in the period 1980-2000; incidence rose in Italian and French populations in the period 1970-2000, in Evros
(Greece) in the 1980s, and in the French West Indies in around 2000.
Conclusions: We conclude that the increase in multiple sclerosis incidence is only apparent, and that it is not
specific to women. Monitoring of multiple sclerosis incidence might be appropriate for the European
Economic Area.
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Multiple sclerosis (MS) is a chronic, demyelinating disease
with frequent worsening episodes denoted as bouts or MS
exacerbations, which are characteristic of the so-called
relapsing-remitting form (RRMS) and absent in the less
common, primary progressive form (PPMS). Despite
intensive research over decades and early identification of
susceptibility genes [1], its aetiology remains poorly
known, with more than 50 susceptibility alleles identified
and a considerable proportion of these regulated by
Vitamin D [2,3]. Environmental factors, probably acting
before adulthood, also appear to be implicated, as
reflected by birth-cohort and season-of-birth effects* Correspondence: jpedro@isciii.es
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distribution, and reproduction in any medium[4,5], selected results of twin studies [6] and changing
incidence among populations migrating to environments
with different risk [7].
The most lively debate surrounding MS epidemiology
at the beginning of the millennium [8-10] could perhaps
be said to have centred on time-related increases in MS
incidence (MSI), whether genuine or ascertainment-
related. Subsequently and due, moreover, to potential
post-vaccination incidents or side-effects of immuno-
modulating therapies, interest in MSI monitoring or
surveillance gained wider recognition [11-15]. Several
MS registers/studies have developed tools for, e.g.,
correcting the effects of diagnostic delays or using
capture-recapture methods, appropriate for improving
the quality and comparability of MSI measurements
[16-18]. Design of incidence thresholds and other alarm
signals may be problematic, since there is considerable
uncertainty worldwide about expected MSI in specificCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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trends, seasonality of bouts and validity of diagnostic
criteria. The goals and formal components of public
health-sponsored surveillance of MS have not yet been
defined.
The purpose of this paper was twofold: firstly, it was
an attempt to describe and compare MSI reported in
recent decades among populations served by medical
systems providing regular access to qualified neurological
expertise, magnetic resonance imaging (MRI) and new
treatments, potentially covered by publicly-run or -funded
national health services, such as those of the European
Economic Area (EEA) Member States. The non-EU
members of EEA (Iceland, Liechtenstein and Norway)
have agreed to enact legislation similar to that passed in
the EU in the areas of social policy, consumer protection,
environment and statistics. Secondly, the paper aimed to
explore and describe the historical presence in the above-
mentioned survey populations of three, specific, potentially
interrelated MS-incidence features: 1) pseudo-periodic
or occasional changes in incidence [19-21]; 2) changes
in magnitude or shape of the age-specific incidence
curve, occasionally reported as bimodal [20,22] and
attributed to an increase in incidence among women
aged over 40 years [10,23,24]; and, 3) a set of interrelated
changes, perceived as a function of calendar time and
interpreted as components of potential alarm signals
(rising incidence of RRMS; increasing female/male
incidence rate ratio and shortened diagnostic delay
from clinical onset) [19,25-28].
Methods
Principles for the undertaking of systematic reviews were
followed [29].
Study identification
We searched for reports in MEDLINE using “Multiple
Sclerosis” and “Incidence”, both as MeSH terms and as
TEXT WORDS issued between 1 January 1965 and 31 May
2012. The search yielded 5317 unrepeated documents.
Analysis of document titles by two authors, EAC and JPC,
searching for issues linked to MSI measurements, enabled
identification by mutual agreement for the purposes of
perusing the abstract (where available) of 344 of the
above-mentioned 5317 documents plus a further six
obtained from one of the author’s files. The same two
authors then examined the abstracts, identified surveys
reporting incidence periods from 1985 onwards, and
mutually agreed on 122 of the above-mentioned 350
documents for full-text review. At a later step, the
following two criteria sets were used for selection of
papers for analysis of age- and sex-specific MSI from
1985 onwards, and time-related changes in MSI in
EEA populations including those predating 1985.Survey selection for studying age- and sex-specific MSI
The quality criteria used for results analyses were: (1) use
of diagnostic criteria explicitly designed for MS/MS
forms; (2) study incidence period either wholly post-1985
or, alternatively, at least two thirds post-1985 in cases
where 1985 was included; (3) provision of age- and sex-
specific measurements. Where different periods were
covered by different reports for the same geographically-
defined population, the most informative (usually the
most recent) was selected. Exclusion criteria were as
follows: (1) lack of reference to MS forms included in
counts; (2) arbitrarily chosen accrual of ≤30 cases; and,
(3) reports in languages other than Danish, English,
French, Norwegian, Spanish or Swedish.
Survey selection for reviewing time-trends or time-related
changes
The quality criteria applied were different and less strict
than those used for age- and sex-specific incidence, and
required that: 1) measurements included either crude or
age- and sex-adjusted incidence rates for an observation
period of, at least, an arbitrary 10-year duration in cases
where 1985 was included; 2) explicit MS diagnostic
criteria were used; 3) figures were based on clinical onset
rather than MS diagnostic periods.
Data-extraction or -completion
Study of age- and sex-specific MSI
A full-text review by both authors of a number of selected
articles on age- and sex-specific MSI measurements in
geographically-defined EEA populations suggested that
there were insufficient or inadequate reported age-group
data to be combined using models, due to one or more of
the following factors: being represented only in graphs
[30-32]; being incomplete for population groups, i.e.,
having numerators with zero cases generally in the
youngest or oldest age-groups [8,33-37]; containing
gross errors in rate calculations, i.e., for incidence in
both sexes [38]; pertaining to age-groups that were too
wide, selected (in general truncated) or mismatched
[39-42]; or corresponding to protracted incidence periods,
i.e., 1965-1993, 1968-1997 or 1975-1994, which probably
encompassed multiple changes in MS diagnostic policies/
traditions that were potentially heterogeneous by age
at onset [43-45]. To complete the data, authors of
reported surveys were thus contacted in specific instances
by JPC via e-mail, correspondence address or telephone
number of their institutional affiliations (usually hospital
departments). Thus, for reports not yet definitely excluded
on the basis of criteria defined in subsection 1.a. above,
the authors of 13 surveys [30-35,37-42,46] were requested
to furnish such data in a different format, e.g., age at clinical
onset instead of age at MS diagnosis, or distribution by age
of incident MS case different to that shown. Subsequently,
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[30-32,37,40] or completed with data extracted from
graphs, specifically from four of them deemed useful
for combination [31,32,37,40]. For 12 surveys, the popula-
tion structure in new age-groups or complementary
demographic data were obtained from the authors or
official statistics bodies [8,30-37,40,46,47]. Eight of the 12
surveys for which new data were requested/obtained
[8,31,32,34-37,40] fulfilled criteria for inclusion of study
results. Since the data from Modena were included in two
different reports [36,47], we studied a total of ten age-and
sex-specific incidence sets drawn from nine different
populations [8,10,31,32,34-37,40,48]. Only two of the
eleven surveys finally selected for study provided
reported data initially deemed valid for analysis pur-
poses [10,48] (see Figure 1 for a summary description
of attrition flow). Reported or obtained numerators
and denominators used for analyses are presented in
the Table 1.Review of time trends or time-related changes
No data were requested from authors for this purpose.
Review results for specific MSI, generally at 5- or,
alternatively, at >5- [8,10,19,21,27,28,34,36,41,47,49-56]
or 1-year calendar time intervals [31,57,58] were obtained
from original reports, disregarding other study-interval
durations. Updated data were used for Ferrara [34,43] and
Catania [10,32].MEDLIN
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Not age- and sex-specific n=70
Age- and sex-specific incidence by time of 
diagnosis n=4
Mainly covering pre-1985 incidence period n=2
No diagnostic criteria (administration) n=1
Data incomplete or deemed inappropiate n=6
Total excluded n=120
Data extracted for results analysis
n=11
Recovered after data completion:
Population denominators n=5
Case and population data n=4
Figure 1 Attrition flow towards study selection.Incidence measurements and comparisons
Rates and specific indicators
For each specific survey, age- and sex-adjusted incidences
were computed using the European standard population.
Female/male (F/M) ratios were obtained, firstly from the
number of cases and secondly from stratified analysis
(Mantel-Haenszel estimator i.e., F/M M-H). Where not
reported, diagnostic delay was calculated from differences
between mean or median ages at onset and diagnosis for
either incidence or diagnostic periods, if mentioned.
Comparative measurements
Incidence rate ratios were obtained from log-linear
models using the binomial distribution. Five analyses
were performed using Poisson models. The core analysis
was conducted by fitting a global model, in which the
independent variables were age-sex, midpoint of study
period and categorised diagnostic criteria. F/M ratios
were computed from models. Time and latitude trends
were described from linear change. Secondary analyses
were conducted separately for populations of: both sexes
aged below 35 years at onset; both sexes aged ≥35 years
at onset; and women or men aged ≥35 years at onset.
Calculations were made using the Stata 11 software
package. Diagnostic criteria were categorised into the
following three variable values: Poser clinically definite
and probable; Poser and McDonald or other MRI
dependent criteria; and other criteria (McAlpine,
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No trends or repeated data n=55
Incidence data by time of diagnosis n=8
No diagnostic criteria (administration) n=1
Total excluded n=99





Table 1 Reported and rearranged data from MS incidence surveys presented in Figure 3
Study Men Women Both
First author Reference Age group Cases Person-years Rate Cases Person-years Rate Cases Person-years Rate
Debouverie 2007 [31] 0-14 0 3,070,347 0.00 7 2,911,480 0.24 7 5,981,827 0.12
15-24 59 2,191,949 2.69 213 2,072,309 10.28 272 4,264,258 6.38
25-34 154 2,236,211 6.89 445 2,199,900 20.23 599 4,436,111 13.50
35-44 151 2,262,937 6.67 339 2,249,492 15.07 490 4,512,429 10.86
45-54 93 1,827,995 5.09 137 1,782,369 7.69 230 3,610,364 6.37
55-64 21 1,458,543 1.44 32 1,542,168 2.08 53 3,000,711 1.77
65+ 2 1,680,520 0.12 5 2,584,219 0.19 7 4,264,739 0.16
Guidetti 1995 [36] 0-14 0 449,088 0.00 0 428,838 0.00 0 877,926 0.00
15-24 12 437,867 2.74 20 424,286 4.71 32 862,153 3.71
25-34 7 429,913 1.63 25 425,059 5.88 32 854,972 3.74
35-44 9 420,283 2.14 16 419,570 3.81 25 839,853 2.98
45-54 1 407,265 0.25 11 409,216 2.69 12 816,481 1.47
55-64 0 384,447 0.00 2 416,345 0.48 2 800,792 0.25
65+ 0 414,027 0.00 0 595,139 0.00 0 1,009,166 0.00
Alonso 2007 [48] 0-14 0 1,114,646 0.00 0 1,061,240 0.00 0 2,175,886 0.00
15-24 6 711,643 0.84 24 700,702 3.43 30 1,412,345 2.12
25-34 50 928,136 5.39 115 926,436 12.41 165 1,854,572 8.90
35-44 57 860,894 6.62 155 837,502 18.51 212 1,698,396 12.48
45-54 51 800,963 6.37 111 780,853 14.22 162 1,581,816 10.24
55-64 29 592,600 4.89 31 596,522 5.20 60 1,189,122 5.05
65+ 5 754,786 0.66 8 1,078,718 0.74 13 1,833,504 0.71
Nicoletti 2005 [32] 0-14 2 297,120 0.67 1 281,850 0.35 3 578,970 0.52
15-24 10 251,490 3.98 19 246,740 7.70 29 498,230 5.82
25-34 22 237,360 9.27 34 240,670 14.13 56 478,030 11.71
35-44 12 205,920 5.83 25 226,150 11.05 37 432,070 8.56
45-54 7 177,620 3.94 17 203,130 8.37 24 380,750 6.30
55-64 3 158,980 1.89 3 193,760 1.55 6 352,740 1.70



















Table 1 Reported and rearranged data from MS incidence surveys presented in Figure 3 (Continued)
Joensen 2010 [40] 0-14 0 125,615 0.00 0 118,653 0.00 0 244,268 0.00
15-24 3 81,263 3.69 6 69,516 8.63 9 150,779 5.97
25-34 5 74,267 6.73 9 63,934 14.08 14 138,201 10.13
35-44 6 75,305 7.97 5 66,389 7.53 11 141,694 7.76
45-54 3 64,103 4.68 5 55,218 9.06 8 119,321 6.70
55-64 0 49,604 0.00 1 44,487 2.25 1 94,091 1.06
65+ 0 59,298 0.00 1 71,896 1.39 1 131,194 0.76
Sundstrom 2003 [37] 0-14 1 255,257 0.40 1 244,079 0.40 2 499,336 0.40
15-24 5 175,802 2.90 14 169,431 8.40 19 345,233 5.60
25-34 18 179,111 10.00 32 166,142 19.20 50 345,253 14.40
35-44 16 182,644 8.70 23 171,520 13.40 39 354,164 10.90
45-54 7 163,908 4.20 12 157,093 7.50 19 321,001 5.90
55-64 0 126,402 0.00 4 131,128 3.10 4 257,530 1.60
65+ 0 189,679 0.00 0 239,325 0.00 0 429,004 0.00
Granieri 2007 [34] 0-14 0 247,388 0.00 2 232,900 0.86 2 480,288 0.42
15-24 10 282,723 3.54 17 267,370 6.36 27 550,093 4.91
25-34 21 370,041 5.68 55 353,479 15.56 76 723,520 10.50
35-44 13 348,169 3.73 41 349,768 11.72 54 697,937 7.74
45-54 8 336,728 2.38 18 350,939 5.13 26 687,667 3.78
55-64 1 331,387 0.30 4 366,978 1.09 5 698,365 0.72
65+ 0 443,139 0.00 2 656,512 0.30 2 1,099,651 0.18
Granieri 2008 [35] 0-14 0 31,856 0.00 0 28,859 0.00 0 60,708 0.00
15-24 2 25,489 7.85 4 24,735 16.17 6 50,196 11.95
25-34 3 35,513 8.45 11 40,625 27.08 14 76,022 18.42
35-44 0 32,290 0.00 5 33,221 15.05 5 65,509 7.63
45-54 2 27,336 7.32 2 27,582 7.25 4 54,887 7.29
55-64 1 22,396 4.47 2 22,356 8.95 3 44,736 6.71



















Table 1 Reported and rearranged data from MS incidence surveys presented in Figure 3 (Continued)
Nicoletti 2010 [10] 0-14 0 129,630 0.00 0 122,860 0.00 0 252,490 0.00
15-24 3 103,300 2.90 13 101,785 12.77 16 205,085 7.80
25-34 10 115,110 8.69 27 114,755 23.53 37 229,865 16.10
35-44 11 104,500 10.53 20 114,380 17.49 31 219,880 14.10
45-54 11 98,320 11.19 8 105,025 7.62 19 198,345 9.58
55-64 4 76,320 5.24 1 91,740 1.09 5 168,060 2.98
65+ 0 111,475 0.00 0 167,980 0.00 0 275,855 0.00
Cabre 2009 [8] 0-14 1 1,388,049 0.07 2 1,351,144 0.15 3 2,739,193 0.11
15-24 6 848,215 0.71 17 837,479 2.03 23 1,685,694 1.36
25-34 8 808,481 0.99 35 926,145 3.78 43 1,734,626 2.48
35-44 7 814,933 0.86 30 931,847 3.22 37 1,746,780 2.12
45-54 2 608,781 0.33 18 699,425 2.57 20 1,308,206 1.53
55-64 1 447,677 0.22 2 511,278 0.39 3 958,955 0.31
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M M-H obtained from prior analysis were used as con-
tinuous variables.
Time-trends
Two independent approaches to time-trends were
adopted. Firstly, time-trends from 1985 onwards were
studied using mid time points for survey data from
models based on ten data sets. Secondly, the reported
time series from incidence surveys providing either
crude, or age- or age- and sex-adjusted figures for pe-
riods encompassing 1985 or after in the EEA were iden-
tified for 19 EEA populations in 21 reports. Trends were
visually examined from crude or adjusted rates plotted
in graphs. When providing the data requested, survey au-
thors occasionally gave their views on the impact had by
changes in patient-management traditions on changes in
incidence: these views will be referred to below as personal
communications.
Results
The above-mentioned 122 documents selected for full-
text perusal generated the 37 articles listed in Table 2
and initially considered for potential data requests. Their
epidemiological features prior to data completion are
shown here mainly for the purposes of assessing possible
selection bias and impact of omissions. In general,
reported incidences referred to all MS forms, with two
surveys providing separate, crude or age- and sex-specific
RRMS and PPMS data [54,59]. Surveys reporting inci-
dence for intervals prior to 1985 covered long study
periods dating back several decades, e.g., up to 1943 for
the Faroes [19,21] and 1955 for Nuoro, Italy [27]. We also
included a survey conducted in San Marino, a mini-state
not formally belonging to the EEA, with human develop-
ment indicators similar to or higher than those of EEA
countries and specialised medical services shared with
Italy [35]. Of the 37 reports, four were used for comparing
age-specific incidence only [35,37,40,48], 16 provided data
for studying trends [19,21,27,28,41,43,49-58] and seven
could be used for both purposes [8,10,31,32,34,36,47]. Ten
studies were excluded [24,26,30,33,38,39,42,46,59,60], four
due to incidences calculated from data sets based on age
at diagnosis, i.e., explicitly reporting MS diagnoses instead
of clinical onsets [30,33,46,60]. The geographical dis-
tribution of studies selected for each purpose is
depicted in Figure 2. Given the political concept of
the EEA, surveys included ethnically, racially and
geographically heterogeneous populations.
Crude and age- and sex- adjusted incidence figures
using the European standard population, data on
diagnostic delay, latitude and mid time point, F/M M-H,
and details of diagnostic criteria for the ten best-quality
surveys are listed in Table 3. Effects of adjustment onincidence figures were modest, with crude figures for
both sexes ranging from 1.14 to 7.93 per 100,000 person
years, and age- and sex-adjusted figures ranging from
1.12 to 7.25 per 100,000 person years, with the extreme
levels for the French West Indies and San Marino
displaying an almost similar 6- to 7-fold variation.
The highest incidence was reported for San Marino
(1990-2005), with Poser definite and probable MS
diagnostic criteria, and the lowest for the French West
Indies (1992-2007), with McDonald criteria. F/M ratios
calculated from case numbers ranged from 1.59 to 4.20,
and those for F/M M-H had a similar range, 1.68 to 3.79,
with figures being lower in the Faroes (1986-2007) and
Catania (1990-1999) and higher in the French West
Indies. The lowest incidence and highest F/M ratios were
seen for the French West Indies. Latitudes varied contin-
entally from 37.3 to 65.0 degrees north, with a 15.2 degree
outlier in the French West Indies. The length of diagnostic
delay from onset was reported in four surveys, all Italian,
ranging from a mean of 21 months in Catania during the
period 1990-1999, to a mean of 6.1 months in Ferrara in
2003 and one month (number of patients nor specified) in
San Marino in 2005. The more recent the study period,
the shorter the diagnostic delay. Poser diagnostic criteria
were used in six surveys [10,31,32,34,35,37], McDonald or
Poser/McDonald criteria combined in three [8,40,48], and
McAlpine’s criteria in the first survey [36]. An aspect that
remained unclear was the likelihood of laboratory-
supported forms being included in Poser’s forms, denoted
by authors as “definite and probable” [8,31,34,35,48], with
the proportion of the laboratory-supported probable cases,
where specified, being 11% [37]. The F/M ratio did not
change with study midpoint using linear regression but
showed a modest, albeit statistically significant, decrease
when the French West Indies survey was excluded, -2.6%
(-4.7%- -0.6%) annually. The F/M ratio decreased signifi-
cantly with latitude, -2.9% (-3.5%- -2.2%) per degree, and
modestly -0.6% (-1.4%- 0.2%) when French West Indian
data were excluded (Table 3). Data were deemed too
sparse for testing linear associations between incidences
and length of diagnostic delays reported in Table 3 (data
not shown), or between incidences and F/M figures.
Age- and sex-specific incidences for ten surveys are
depicted in Figure 3. In general, incidence among women
was nil at ages under 15 (five surveys) and ≥65 years, and
low at ages 55-64 years, peaked at 25-34 years in general
and at 35-44 years solely in the UK study, frequently
reaching values of 20-30 per 100,000. The lowest
figures were seen: for the survey conducted in Reggio
Emilia-Modena in 1985-1990, using Poser criteria; and
in particular, for the recent study conducted in the
French West Indies in 1992-2007 using McDonald’s
revised criteria. Among men, age-specific incidence
was less stable and lower, suggesting a trend to peak
Table 2 Epidemiological features of selected studies
Study population Study period Study Sex- and age-
specific counts
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1 Faroe Islands 1943-2007 81 NO <1986 Poser CD,CPr Mean age at onset NO 1.25 Trend
Denmark 65 >1986 Poser, 32y
Joensen 2011 [19] 7 McDonald and Thompson
2 South-west Sardinia 1958-2007 YES McDonald - NO None
Italy 50
Cocco 2011 [33] 5
3 Iceland 2002-2007 136 YES Poser CD for Mean age at diagnosis 36.3y YES 3 None
Eliasdottir 2011 [46] 6 PPMS Mean age at onset 32y
1
4 Oppland 1989-2001 148 NO Poser D and Pr, otherwise NS - NO 2.02 Trend
Norway 13
Risberg 2011 [55] 3
5 Faroe Islands 1986-2007 43 YES Poser and/or McDonald,
for PPMS
36y at onset NO 1.53 Age- and sex-specific
incidence
Denmark 22
Joensen 2010 [40] 1
6 Ostrobothnia 1992-2007 374 NO Poser CD Mean age at onset 31.7y NO None
Finland 16 McDonald CD Mean age at diagnosis 35.9y
Krokki 2010 [24] 1
7 Catania 1975-2004 367 (75-04) YES Poser CD,Cpr,LSPr Mean DD 1.4y NO 1.55 Both
Italy 30 108 (00-04) Age at onset increasing
with time
Nicoletti 2011 [10] 6
8 Cardiff (Wales) 1985-2007 582 NO Poser and McDonald - NO 2.83 None
United Kingdom 23 (otherwise NS)
Hirst 2009 [38] 1
9 West Indies 1992-2007 130 YES Revised McDonald Mean age at onset 34.2y YES 4.2 Both
France 15



















Table 2 Epidemiological features of selected studies (Continued)
10 San Marino 1990-2005 33 YES Poser D,Pr Mean DD decreasing with
time (1.5 to 0.08y)
YES 3.12 Age- and sex-specific
incidence
Italy 16
Granieri 2008 [35] 1
11 Greece 3 regions 1984-2006 834 NO Poser and McDonald D Mean DD 2.62y decreasing




23 (otherwise NS) Mean age at onset 31.41y
4
12 Ferrara 1965-2003 200 (90-03) YES Poser CD,CP Mean DD decreasing with
time (1.25 to 0.5y)
YES 2.21 Both
Italy 39 421 (65-03)
Granieri 2007 [34] 4
13 UK cohort 1993-2000 642 YES Poser D,Pr, - NO 2.24 Age- and sex-specific
incidence
Alonso 2007 [48] 8 McDonald D,Pr
1
14 Lorraine 1990-2002 1658 YES Poser D,Pr - YES 2.45 Both
France 13
Debouverie 2007 [31] 1




Grytten 2006 [51] 10
16 Nordland 1970-1999 259 (70-99) YES Poser Mean DD 4.7y YES 1.87 None
Norway 30 183 (85-99) CDPr,,LSDPr Mean age at diagnosis 39y
Alstadhaug 2005 [30] 6
17 Catania 1975-1999 155 (90-99) YES Poser CDPr,LSDPr Mean at onset 33.3y YES 1.77 Both
Italy 25 Mean DD 1.7y
Nicoletti 2005 [32] 5
18 Sassari 1965-1999 689 NO Poser DD range 13.0-0.9y decreasing
with time
NO 2.57 Trend
Italy 34 Age at onset increasing
with time
Pugliatti 2005 [54] 7
19 Monreale City 1981-2000 19 YES Poser D,Pr Mean DD 9.2y NO - Trend
Italy 20
Ragonese 2004 [41] 2



















Table 2 Epidemiological features of selected studies (Continued)
Greece 26
Piperidou 2003 [53] 5
21 Vasterbotten County 1988-1997 133 YES Poser - NO 1.83 Age- and sex-specific
incidence
Sweden 10
Sundström 2003 [37] 1
22 Finland 3 districts 1979-1993 1066 NO Poser CD or Lublin et al for PPMS Mean age at diagnosis for
districts (35.7,39.3,39.7y)
NO 1.6 None
Sumelahti 2003 [59] 15
2
23 Lower (Bajo) Aragon 1985-2002 42 NO Poser CD,CPr DD 2y NO 1.93 Trend
Spain 18 Mean age at onset 29y
Modrego 2003 [58] 1
24 Padova 1980-2000 580 NO Poser Decreasing DD with time NO 1.92 Trend
Italy 20 34y
Ranzato 2003 [28] 4
25 Iceland 1951-1999 372 NO Poser - NO 1.9 Trend
Benedikz 2002 [49] 49
10
26 Faroe Islands 1943-1994 54 NO Poser CD,CPr Individual age at onset available NO - Trend
Denmark 52
Kurtzke 2001 [21] 8
27 Enna, Sicily 1986-1995 16 YES Poser Mean DD 3y NO 1.28 None
Italy 10
Grimaldi 2001 [39] 1
28 Oslo 1972-1996 794 NO Poser CD For persons diagnosed
1986-1999
NO 2.38 None
Norway 25 DD 5.2y
Celius 2001 [26] 5 Age at diagnosis 38.1y
29 Nuoro 1955-1995 469 YES Poser (unspecified),
Allison & Millar and
Schumacher
Mean DD 4.61y NO 1.95 Trend
Italy 41 Mean age at onset 28.5y
Granieri 2000 [27] 8
30 Alcoi 1986-1997 45 NO Poser CD,CPr - NO 4 Trend
Spain 12 Mean age at onset 35.1y



















Table 2 Epidemiological features of selected studies (Continued)
31 Troms & Finnmark 1974-1992 139 NO Rose DPrPs & Mean DD 4.5y NO 1.36 Trend
Norway 19 Poser CD,CPr,LSD Mean age at onset/diagnosis
available
Gronlie 2000 [50] 4
32 Bagueria city 1985-1994 20 YES Poser Age at diagnosis 34.6y NO 1.86 None
Italy 10 Mean DD 2.6y
Salemi 2000 [42] 1
33 North-western Sardinia 1962-1991 277 YES Poser CD,CPr,LSD,LSPr DD range 8.0-1.8y decreasing
with time
NO 2.46 Trend
Italy 30 Mean age at onset 27y
Rosati 1996 [56] 6
34 Ferrara 1965-1993 252 YES Poser CD,CPr DD range 6.1-1.9y decreasing
with time
NO 2.07 Trend
Italy 29 Mean age at onset for specific
forms
Granieri 1996 [43] 6
35 More & Romsdal 1950-1991 330 NO McAlpine DD potentially available 6y NO 1.41 Trend
Norway 42 39.2y
Midgard 1996 [52] 8
36 Reggio Emilia & Modena 1970-1990 316 (70-90) YES McAlpine CD,CPr - YES 2.01 Both
Italy 6 105 (85-90) Mean age at onset 30.75y
Guidetti 1995 [36] 4
37 Modena 1970-1990 183 (70-90) YES McAlpine D,Pr - YES 1.9 Both
Italy 6 59 (85-90) Mean age at onset 30.8y



















1-Faroe Islands, Joensen 2011. 
4-Oppland, Risberg 2011.
5-Faroe Islands, Joensen 2010
7-Catania, Nicoletti 2011.
9-French West Indies, Cabre 2009.
10-San Marino, Granieri 2008.
12-Ferrara, Granieri 2007.
13-United Kingdom, Alonso 2007.
14-Lorraine, Debouverie 2007.
15-Hordaland, Grytten 2006. 
17-Catania, Nicoletti 2005.




23-Lower Aragon, Modrego 2003.
24-Padova, Ranzato 2003.
25-Iceland, Benedikz 2002.
29-Nuoro, Granieri 2000 .
30-Alcoi, Mallada 2000.
33-NW Sardinia, Rosati 1996.
35-More & Romsdal, Midgard 1996.
36-Reggio Emilia & Modena, Guidetti 1995.




























Figure 2 Geographical distribution of MS surveys included in age-specific incidence analysis (top) and time trends (bottom).
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http://www.biomedcentral.com/1471-2377/13/58at later ages in some recent surveys in the UK and
Catania [10,48].
Results from log-linear models are described in Table 4.
We used ten data sets from surveys undertaken in
different, independent populations, fulfilling selection
criteria for the study of age-and sex-specific incidence.
Lorraine, a large and well-conducted study, was chosen
as reference, and ages 25-34 and 35-44 years at onset
were the reference for comparisons when analyses were
restricted to ≤34 and ≥35 years respectively. Results were
in general similar for the core analysis, women, men,
ages below 35 years at onset and ages >35 years at onset,
with negligible differences. As seen from the core model,
7-fold differences in RRs were seen, with differences in
RRs in Catania, 1.39 (1.01-1.91), Reggio Emilia-Modena,
0.33 (0.24-0.45), and the French West Indies, 0.20 (0.16-
0.29) proving statistically significant. Incidence among
women was triple that of men 2.9 (1.87-2.57). The mean
increase in incidence with time was 9% (4%-15%) per year
in both sexes. Incidence was different when measured
using MRI-based criteria (McDonald criteria included) in
the core model, RR 0.68 (0.55-0.85).
Complementary analysis revealed some discrepancies.
Models for ages ≥35 years revealed the highest incidences
in the UK, 1.66 (1.30-2.13), and Catania, 1.43 (1.02-2.61),
with an F/M ratio of 1.96 (1.67-2.31), 1/3 lower than
those seen for the younger age groups. The analysis of
men aged ≥35 years at onset showed the highest, 20%(7%-34%), statistically significant increase in incidence
per year, which almost tripled that seen among women
of the same age, i.e., 7%. MRI-based diagnostic criteria had
the highest impact on populations aged ≤35 years, 0.43
(0.35-0.53). When separate models were adjusted for age
and sex, the above-mentioned incidence increased with
study midpoint, i.e., ages ≥35 years in both sexes, by 12%
(5%-20%) annually, together with a 5% (3%-6%) increase
per degree of latitude, present across all age- and sex- or
age-groups. The increase per degree of latitude was signifi-
cant and rose with age and male sex, ranging from 3% for
both sexes aged ≤34 years to 6% for men aged ≥35 years.
Time series from selected surveys are depicted in
Figure 4. Seven reports on Nordic, eight on Italian,
and two on Greek and French Caribbean populations
covered 5- to 10-year incidence figures for long periods
from 1943 to 2007. Three surveys, one French and two
Spanish, furnished time-series data for annual counts for
the period 1985-2002. In general, MSI increased with:
(a) high figures in northern and southern continental
populations, reaching four to seven per 100,000
person-years but plotting different shapes, i.e., sharply
decreasing in the most recent study period in northern
populations (frequently attributed by authors to in-
complete case-finding due to diagnostic delay) and yet
increasing in Italian populations; and, (b) lower incidences
in Greek and French Caribbean populations. Profiles from
annual counts were difficult to assess for Alcoi and Lower
Table 3 Selected data from surveys with available age- and sex-specific incidence for periods of clinical onset in EEA populations
Survey population No.
cases
Diagnostic criteria Incidence Stratified F/M Diagnostic delay Mid time point Latitude
Incidence period Crude F/M M-H ratio Months Year
Degrees NPerson/years Adjusted Mean/median DD
(1987-2000)
Reference Women Men Both
Lorraine 1658 Poser D,Pr, (NSO) 7.68 3.26 5.51 2.50 2.45 - 1996 49
1990-2002 7.76 3.16 5.43 (2.24-2.77)
30070439
Debouverie 2007 [31]
Reggio Emilia & Modena 105 Mc Alpine D,Pr (NSO) 2.37 0.99 1.70 2.58 2.55 - 1987.5 44.28
1985-1990 2.45 0.95 1.69 (1.68-3.97)
6061343
Guidetti 1995 [36]
United Kingdom 642 Poser D,Pr or MacDonald D,Pr (NSO) 7.42 3.44 5.47 2.26 2.24 - 1996.5 53.51
1993-2000 7.45 3.30 5.36 (1.91-2.67)
11745641
Alonso 2007 [48]
Catania 155 Poser CDPr,LSDPr 5.87 3.65 4.81 1.68 1.77 21 m 1994.5 37.3
1990-1999 6.02 3.58 4.84 (1.21-2.33)
3221760
Nicoletti 2005 [32]
Faroe Islands 43 Poser CD, LSD, or McDonald for one
attack (separate criteria for PPMS forms)
5.51 5.21 4.32 1.82 1.59 - 1996.5 62.01
1986-2007 5.90 5.23 4.48 (0.99-3.35)
1019548
Joensen 2010 [40]
Västerbotten 133 Poser CDPr, LSDPr 6.73 3.69 5.21 1.94 1.83 - 1992.5 65.02
1988-1997 7.23 3.72 5.43 (1.36-2.77)
2551521
Sundström 2003 [37]
Ferrara 200 Poser D,Pr (NSO) 5.39 2.25 3.83 2.66 2.62 15.4 m (in 1990) 1996.5 44.5





















Table 3 Selected data from surveys with available age- and sex-specific incidence for periods of clinical onset in EEA populations (Continued)
San Marino 33 Poser D,Pr (NSO) 11.69 3.96 7.93 2.95 3.13 18.3 m (in 1990) 1997.5 43.56
1990-2005 10.46 3.80 7.25 (1.32-6.56) 1 m (in 2005)
415540
Granieri 2008 [35]
Catania 108 Poser CDPr,LSDPr 8.43 5.28 6.94 1.69 1.77 17 m 2002 37.3
2000-2004 8.72 5.24 6.96 (1.14-2.49)
1549580
Nicoletti 2011 [10]
French West Indies 130 2005 revised McDonald (NSO) 1.75 0.46 1.14 3.79 4.20 - 2000 15.2
1992-2007 1.71 0.44 1.12 (2.45-5.87)
11434927
Cabre 2009 [8]
Beta for F/M M-H in ordinates linear
regression
- - - - - - - -
All data sets 0.022 -0.029
(-0.006, 0.05) (-0.035, -0.022)
(French West Indies excluded) -0.026 -0.006



















Figure 3 Age-and sex-specific incidences of selected EEA surveys.
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http://www.biomedcentral.com/1471-2377/13/58Aragon (Spain) [57,58] due to unstable data, and clearly
increasing for Lorraine (France) [31].
The full panorama appears to provide three different
geographical and calendar-time related patterns as
determined by the increasing rates, ranging from two
to seven per million, and lags of approximately 10-20
calendar years. These patterns were as follows: first,
northern populations generally exhibited rising incidences
in the 1960s, 1970s and 1980s, with a drop in incidence in
the most recent study period, and a complex, different
profile with low incidence in the Faroes during the period1960-1970 [19,49,51,55]; second, Italian populations
showed heavily increasing rates from 1-2 to 6-7 per
100,000 during the 1970s, occasionally with a delay of one
or more decades, such as the increase in Nuoro which was
paralleled 15 years later by Catania and Lorraine, a French
mainland population which, since 1990, has registered a
magnitude and trend similar to that of Catania; and third,
populations in Evros, Greece 1974-1999, where the
starting point was the lowest among those studied, 0.66
per 100,000, and the French West Indies 1992-2007,
which displayed a rise within a narrow range of 1-2.5 per
Table 4 Results from log-linear models (binomial function), OR and 95%CI
Core analysis Both sexes Both sexes Women Men
Study population, incidence period All ages both sexes Age at onset <35y Age at onset ≥35y Age at onset ≥35y Age at onset ≥35y
First author and reference Lorraine 1990-2002 1 1 1 1 1
Debouverie 2007 [31]
Reggio Emilia 85-1989 0.33 0.37 0.25 0.28 0.18
Guidetti 1995 [36] (0.24-0.45) (0.29-0.48) (0.17-0.36) (0.19-0.42) (0.09-0.37)
UK cohort 1993-2000 1.22 0.57 1.66 1.59 1.55
Alonso 2007 [48] (0.94-1.59) (0.48-0.66) (1.30-2.13) (1.28-1.96) (1.03-2.35)
Catania 1990-1999 0.98 0.90 0.87 0.84 0.90
Nicoletti 2005 [32] (0.72-1.32) (0.72-1.12) (0.63-1.20) (0.61-1.17) 0.53-1.50)
Faroe Islands 86-2007 0.94 0.83 0.91 0.80 1.02
Joensen 2011 [19] (0.63-1.39) (0.55-1.25) (0.57-1.48) (0.45-1.45) (0.49-2.10)
Västerbotten 88-1997 1.07 1.03 1.00 0.96 1.02
Sundström 2003 [37] (0.79-1.46) (0.81-1.32) (0.72-1.39) (0.68-1.36) (0.61-1.70)
Ferrara 90-2003 0.74 0.79 0.64 0.74 0.49
Granieri 2007 [34] (0.55-0.99) (0.65-0.97) (0.48-0.86) (0.55-0.98) (0.29-0.81)
San Marino 90-2005 1.44 1.43 1.19 1.34 0.81
Granieri 2008 [35] (0.93-2.23) (0.92-2.23) (0.66-2.15) (0.71-2.54) (0.25-2.61)
Catania 2000-2004 1.39 1.19 1.43 1.06 2.07
Nicoletti 2011 [10] (1.01-1.91) (0.90-1.57) (1.01-2.00) (0.72-1.57) (1.26-3.38)
West Indies 1992-2007 0.21 0.19 0.21 0.26 0.11
Cabre 2009 [8] (0.16-0.29) (0.15-0.25) (0.15-0.29) (0.19-0.35) (0.06-0.22)
Age-groups 0-14y 0.01 0.01 - - -
(0.008-0.02) (0.008-0.02)
15-24y 0.50 0.47 - - -
(0.39-0.64) (0.42-0.52)
25-34y 1 1 - - -
35-44y 0.84 - 1 1 1
(0.67-1.04)
45-54y 0.56 - 0.66 0.61 0.71
(0.44-0.71) (0.55-0.78) (0.52-0.71) (0.52-0.97)
55-64y 0.19 - 0.21 0.17 0.29
(0.14-0.25) (0.17-0.27) (0.14-0.22) (0.20-0.44)



















Table 4 Results from log-linear models (binomial function), OR and 95%CI (Continued)
(0.01-0.04) (0.01-0.04) (0.01-0.04) (0.01-0.06)
Sex (reference men) 2.19 2.81 1.96 - -
(1.87-2.57) (2.51-3.14) (1.67-2.31)
Mid time point incidence period * 1.09 1.06 1.12 1.07 1.20
(1.04-1.15) (1.01-1.12) (1.05-1.20) (0.99-1.15) (1.07-1.34)
Latitude degrees* 1.04 1.03 1.05 1.04 1.06
(1.03-1.05) (1.02-1.04) (1.03-1.06) (1.02-1.05) (1.03-1.08)
Diagnostic criteria* Poser 1 1 1 1 1
Other than Poser’s (McAlpine) MRI data
not considered
0.73 0.71 0.77 0.59 0.99
(0.41-1.30) (0.40-1.26) (0.35-1.67) (0.25-1.41) (0.25-3.87)
McDonald or Poser and MacDonald
including MRI evidence of spread
0.68 0.43 0.94 1.06 0.76
(0.55-0.85) (0.35-0.53) (0.71-1.22) (0.80-1.41) (0.49-1.26)



















Figure 4 Time trends of reported MSI in the following EEA populations: (left) Nordic; (centre) Italian, Greek, and French Caribbean;
(right) French mainland and Spanish.
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then appeared, after a 15-year delay, in the French West
Indies [8,10,27,32,53].
To sum up, in post-1980 periods rates of close on
6-8 per 100,000 were seen in the majority of EEA
populations, preceded by increasing and already stable
trends in some Nordic (Hordaland, Oppland, Iceland),
Italian (Nuoro, Sassari), and French mainland (Lorraine)
populations; meanwhile, low but rising figures of 1-3 per
100,000 were still being seen at the end of the century
in Greek and Caribbean populations. Where described,
variations in incidence were reflected in all age-groups
and both sexes. The time-related change (slope) in
Nordic populations before the 1980s appeared to be
replicated during the 1980s and 1990s by Italian and
French populations, and at a later stage, during the
1990s and beyond, by Greek and French Caribbean
populations, which solely show rising figures and
shorter study periods.
Discussion
The results of this study show that, in recent decades,
MSI in EEA populations has been measured using
different methods, geographically selected by residence,
and has sometimes been reported by age and calendar
time at “MS diagnosis”, a health-care variable that is easier
to identify than that which it has replaced, i.e., “clinical
onset”. Post-1985 results suggest a dynamic picture of
MSI, with regular features (peak values for women aged
25-34 years, similar F/M ratios which are higher in the
young age strata and youngest populations) and seven-
fold variations which are better explained by local changes
than by links to latitude (3-fold across 50 degrees latitude,
but small if continentally considered) or time (a 2-fold
increase per decade). The historical time series suggest
increases, initially in the north and more recently in the
south, reaching similar levels, 5-7 per 100,000 population,
with figures that are still low in Greece and the French
Caribbean. These results do not reveal temporal drops
in incidence, except for the Faroes, age-specific bimodalityor rising incidences in women linked to an increase in the
F/M ratio. When it comes to data analysis and interpret-
ation of results, limitations include: infrequent description
of temporal relationships between the diagnostic process
and end of case-finding periods; lack of systematic
assessment of impact of health service innovations on
MS diagnosis (not systematically searched for); and
cultural-behavioural differences on seeking diagnosis
after mild symptom onset.
Selection might partly account for our results, firstly
due to the choice of population by EEA neurologists
conducting surveys. Secular trend analysis was mainly
based on two very different but relatively homogeneous
populations and medical services, i.e., Nordic and Italian.
This bipolar pattern was not present in post-1985
data, in which Nordic populations were comparatively
underrepresented. Interestingly, the large, sevenfold,
variation is evident in both data sets, secular and
post-1985, and is therefore unlikely to have been
biased in the same direction by selection. Selection
might have been determined by exclusion of surveys
reporting age and time-point at MS diagnosis. A data
plot of some surveys rejected due to incidence being
calculated by age-at-diagnosis [26,30,33,46,60] indicates
that three incidence features, namely, high magnitude,
increase in incidence among persons aged ≥35 years and
rising time trends, are more clearly revealed when seen
from new diagnoses (see Figure 5) than from onsets in
Figure 3. This view suggests that the increase in MS
diagnoses is higher than the increase in MS onsets. The
shortening of MS diagnostic delays in post-1985 surveys,
likely restricted to the RRMS form [54], has frequently
been described in Italian populations [28,54] but such in-
tervals tend to be more stable in Nordic populations [59].
Diagnostic delay after symptom onset decreased from five
years in the mid- or late 1980s in Norway and Italy to two
years in the last decade in Spain [26,28,61]. We be-
lieve that part of the rise in MS incidence reflects im-
proved access to neurological services at ages considerably
later than age at MS onset, with it being impossible, in
Figure 5 Data based on age at or year of MS diagnosis.
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ture patients who never reach neurological experts.
The different age-specific incidence profile and results
from complementary analysis showing the highest risk
among women aged ≥35 years, suggest that the large
UK survey [25] might contain a large proportion of
women misclassified by age due to inaccurate reporting of
onsets. The use of McDonald’s or theoretically more
sensitive mixed criteria [62] was associated with low
incidence, a paradox probably explained by the fact
that such criteria were applied in survey locations and
study periods when MSI was low, such as the French
West Indies. The high F/M ratio in the young West
Indian population and stable trend are consistent with
the stable F/M ratios observed for incident patients
registered in Sweden over the period 1946-2005 [63].
Time-related changes in post-1985 measurements
were few, with the most relevant possibly being the rise
in incidence among ≥35-year-olds. Bimodality by age at
onset, as described in old surveys on black populations
in the USA and recently suggested in Newcastle
(Australia) for the period 1986-1996 [64], was not in
evidence in our data. The explanation for both our and
the Newcastle figures might conceivably lie in the capture
of silent, mild MS cases by age-differential ascertainment,
underlying age-differential access to neurological diagnosis
bimodality in old surveys [22,65-67]. The low, extensively
studied, incidences in the Faroe Islands, the modest de-
creasing trend in Hordaland for the 1980-1995 midpoint
interval, and the occasional decline registered in Denmark
[20] remain unexplained.
While substantial, several-fold variation in MSI was
linked to place and only twofold variation was linked
to latitude or time, such variation was not linked to
more sensitive, MRI-based diagnostic criteria [33,40].MS registration in Nordic populations, and more recently
in Ferrara or Catania, shows that the magnitude of local
change matches recorded international differences across
longer periods and affects all age and sex groups.
Improvement in diagnostic ascertainment across all ages
in recent decades is evident from improved access to
neurological expertise, laboratory testing and MRI, and is
frequently reported in Nordic and Italian studies. The fact
that earlier low incidence persists being low after prolonged
survey updates in Ferrara, Catania and Hordaland,
may suggest that diagnostic improvement basically
affects clinically recent and mildest MS forms. Such
ubiquitous factor might explain secular and post-1985
time trends in the EEA. This interpretation is difficult
to reconcile with two views held by local researchers
claiming a true increase in MSI: first, that suggested
by Italian and mainland-based French neuroscientists,
whereby the increase is said to be attributable to the
biological impact of changes in women’s life-style
[10,23,31,44]; second, that relatively restricted to
returning continental immigration, reported in the
French West Indies as a lagged phenomenon imported
from a higher-risk environment [8,68]. Major reasons
for rejecting such interpretations or modulating them
in favour of better detection in mild cases are: (1) that
the increase in MSI among women or older women is,
if anything, restricted to single surveys (not seen
here), and that changes in EU women's lifestyles (e.g.,
occupational) were generalised and predated studies
on Scandinavian populations not showing such an
increase, (http://www.ilo.org); (2) that rising MSI in
the French West Indies pertains to particularly severe
forms [8,69], thus potentially representing the tip of
the iceberg already uncovered in the majority of other
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Figure 6 Outline of the framework for registry-based MS monitoring on different EEA populations, assuming stable annual MSI (N
onsets per year) and MS diagnostic improvement secondary to synergistic effects of improved access to neurological expertise (NE),
CSF oligoclonal bands, neurophysiological tests and visual evoked potentials (CSF-EP), and magnetic resonance imaging (MRI).
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or childhood hygienic changes, race and latitude, we
would prefer to propose that increased population
concern about MS symptoms, referral and access to
neurological expertise and, recently, to technology
acting on stable MSIs might account for the entire
EEA pattern, particularly due to the increasing proportion
of women active in non-domestic occupational work
among those of working age in EEA-surveyed populations.
The geographically and time-related decreasing differences
in MSI in the EEA by asymptotic trend towards an
incidence of 5-7 per 100,000, may suggest that MS
appears to behave invariantly with respect to time and
space at a stage characterised by improvements in diagnosis
and treatment, and by the loss of the natural history
due to the widespread use of immune-modulatory
treatments that are partly effective and not free of
side-effects [70,71]. MS diagnostic functions at EEA
might mirror the parallel logarithmic or sigmoid functions
outlined in Figure 6. Such pattern defines a framework
that is inevitably present in different approaches (surveys,
registries, monitoring systems), potentially providing what
are apparently diverging but are, in reality, consistent
results on different patients. On combining worldwide
data from 38 incidence periods reported in 1966-2007, i.e.
the global longitudinal approach, Alonso and Hernan [25]
describe increasing time-trends for incidence and F/M
ratios attenuated after 1980, findings that are consistent
with ours. Register-based, calendar-time-limited incident
approaches (see the post-1985 window in Figure 6) and
prevalence approaches [72] accumulate an increasingproportion of frequently treated cases detected in high-
incidence settings.
Given the suggested difficulties found in measuring
MSI, it would appear that the proposal of a pilot surveil-
lance system active under suspect alarm conditions,
similar for instance to those designed and tested for
Guillain-Barré syndrome [73], may not be opportune for
a number of reasons (lack of reported outbreaks or an
expected preventive response, problems managing
suspected cases), at least until MSI levels exceed those
described for Nordic populations or new aetiological
agents are identified. Instead, some of the existing moni-
toring alternatives appear to be reasonable, subject to
being population- rather than hospital-based. Fortunately,
there is long experience of monitoring EEA populations.
Conclusions
We conclude that the reported rising incidence of MS
in the EEA might be attributable to improved ascer-
tainment and that population-based MS monitoring by
selected centres may be useful.
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